Author:
Kupersmith Mark J.,Jette Nathalie
Abstract
AbstractThere are many reasons why the majority of clinical trials fail or have limited applicability to patient care. These include restrictive entry criteria, short duration studies, unrecognized adverse drug effects, and reporting of therapy assignment preferential to actual use. Frequently, experimental animal models are used sparingly and do not accurately simulate human disease. We suggest two approaches to improve the conduct, increase the success, and applicability of clinical trials. Studies can apply dosing of the investigational therapeutics and outcomes, determined from animal models that more closely simulate human disease. More extensive identification of known and potential risk factors and confounding issues, gleaned from recently organized “big data,” should be utilized to create models for trials. The risk factors in each model are then accounted for and managed during each study.
Funder
New York Eye and Ear Infirmary Foundation
Alfiero & Lucia Palestroni Foundation, Inc.
National Eye Institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference43 articles.
1. Fernie J.A. Penning-van Beest, Fabian Termorshuizen, Wim G. Goettsch, Olaf H. Klungel, John J.P. Kastelein, Ron M.C. Herings, Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study Eur Heart J. 2007; 28:154–159, https://doi.org/10.1093/eurheartj/ehl391
2. Stella S. Daskalopoulou, Joseph A.C. Delaney, Kristian B. Filion, James M. Brophy, Nancy E. Mayo, Samy Suissa, Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J. 2008; 29: 2083–2091, https://doi.org/10.1093/eurheartj/ehn346
3. Øvrehus K, Diederichsen A, Grove E, et al. Reduction of myocardial infarction and all-cause mortality associated to statins in patients without obstructive CAD. J Am Coll Cardiol Img. 2021;14:2400–10. https://doi.org/10.1016/j.jcmg.2021.05.022.
4. Byrne P, Demasi M, Jones M, Smith SM, O’Brien KK, DuBroff R. Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis. JAMA Intern Med. 2022;182:474–81. https://doi.org/10.1001/jamainternmed.2022.0134.
5. Baker R, Fraser RC, Stone M, Lambert P, Stevenson K, Shiels C. Randomized controlled trial of the impact of guidelines, prioritized review criteria and feedback on implementation of recommendations for angina and asthma. Br J Gen Practice. 2003;53:284–91.